Transcript Highlights:

• acts where a delivery of a substances acts where a delivery of a controlled<00:01:16.560><c> substance
• And then we jump substances deliveries.
• </c><00:02:50.720><c> Act</c> violates the Controlled Substances Act violates the Controlled Substances
• </c> kids who have used or abused substances. kids who have used or abused substances.
• more substances that are coming along that we're just simply not aware of.

Bills: SF0009

Committee: House Judiciary

Transcript Highlights:

• There's only substances that will be able to be bad.
• Many of the clients we represent have a substance use or a co-occurring substance use and mental health
• To use substances.
• It's just that the substance is legal in those places.
• So when people are using, they're getting substances.

Committee: Joint Joint Committee on Mental Health, Substance Use and Recovery

Summary: The Joint Committee on Mental Health, Substance Use, and Recovery held a public hearing on several harm reduction bills, including measures to decriminalize simple possession and paraphernalia, authorize overdose prevention centers, and expand access to naloxone for first responders. Chair Mindy Domb and Senator John Velis opened by describing harm reduction as an evidence-based public health strategy and noting Massachusetts’ recent decline in fatal overdoses. They emphasized that testimony would help shape whether and how the bills advance, and explained the hearing process, including time limits and written testimony. Testimony was sharply divided. Supporters, including Rep. Kate Donaghue, Sen. Cindy Friedman, Rep. Marjorie Decker, Rep. Manny Cruz, public health professionals, recovery advocates, and people with lived experience, argued that harm reduction saves lives, reduces stigma, and can connect people to treatment. They supported overdose prevention centers and decriminalization as tools to keep people alive long enough to enter recovery, and several speakers described personal losses to overdose or family experiences with addiction. Some supporters also framed the bills as racial justice measures, arguing that criminal penalties for possession have disproportionately harmed Black and brown communities. Opponents, including Sen. Nick Collins and several South End residents, argued that overdose prevention centers and decriminalization would worsen public drug use, crime, and neighborhood disorder, especially around Mass and Cass. They said current approaches such as Section 35, diversion, and police leverage into treatment are more effective, and they urged more treatment beds and recovery facilities instead of harm reduction sites. Committee members questioned witnesses about research, local siting, crime data, and the relationship between harm reduction and treatment, and several members said neighborhood impacts must be considered alongside overdose prevention. The committee did not take a vote during the hearing; it continued receiving testimony and announced a later break before resuming on H. 2196 and S. 1393.

Transcript Highlights:

• My master's degree is in substance use counseling and education.
• I had a strong focus on substance use and mental health.
• Substance such as cannabis? I myself couldn't.
• One is with the 'or any intoxicating substance' language.
• There's a reason we list out alcohol, controlled substance, chemical substance; good public policy to

Committee: Senate Criminal Justice

Summary: The committee heard a presentation from Jessica Spencer on cannabis, criminal justice, and mental health. She argued that marijuana products have become far more potent over time, that high-potency THC and hemp-derived products are widely available in Florida, and that daily or near-daily use can contribute to addiction, psychosis, and other mental health problems, especially for adolescents. She also said cannabis is linked to violent crime and suicide in some cases, urged more prevention funding in schools, stronger regulation of Delta-8 and similar products, better law enforcement and regulatory oversight, expanded treatment and diversion options, and more expungement opportunities for simple possession. Senators questioned her about potency data, testing methods, and whether she was claiming causation in violent cases; she said she was and noted she had worked on the No on 3 campaign while still favoring decriminalization of simple possession rather than full legalization. The committee then took up several bills. CS/SB 150, “Trooper’s Law,” was amended and reported favorably; it makes extreme animal cruelty during a declared emergency a third-degree felony, inspired by the rescue of a dog during Hurricane Milton. SB 234, the Jason Rayner Act, was reported favorably after debate over its changes to self-defense language and mandatory life imprisonment for manslaughter committed against a law enforcement officer; supporters said it closes a loophole exposed in the Rayner case, while opponents raised concerns about unintended consequences and mandatory sentencing. CS/SB 138, “Trenton’s Law,” also passed after amendment; it increases penalties for repeat DUI/vehicular homicide offenders and adds language on intoxicating substances, with supporters citing the death of Trenton Stewart and opponents warning about cannabis impairment standards and first refusal penalties. SB 130, dealing with compensation for wrongful incarceration, was reported favorably. The bill removes Florida’s “clean hands” bar, extends the filing deadline from 90 days to two years, and allows exonerees with factual innocence findings to pursue compensation and civil remedies. Support came from innocence and civil liberties advocates. The committee also received a law enforcement presentation from Florida Highway Patrol Lieutenant Channing Taylor on impaired driving enforcement, DRE training, and crash data, emphasizing that drug impairment—especially cannabis—plays a major role in fatal crashes and that officers rely on observation and field testing because roadside chemical testing is limited.

Transcript Highlights:

• Substance use during adolescence is high.
• Substance use during adolescence is high.
• They do not require a formal substance use disorder diagnosis.
• It is free, substance-use-free, pro-social activities.
• This Substance Abuse and Mental Health Services Administration.

Summary: The meeting opened with approval of the April minutes and brief administrative updates, including notice that House Bill 5447 had passed both chambers of the General Assembly. Speakers reflected on the bill’s key provisions, which include eating-disorder working groups, an evidence-based screening requirement for school-based health centers beginning July 1, 2027, and a DSS-led feasibility process to explore an inpatient psychiatric facility for young adults ages 14 to 21. New staff introductions were also made for the Behavioral Health Advocate’s office and the TCB team. A major portion of the meeting focused on marketing and outreach for urgent crisis centers (UCCs) and the broader youth crisis continuum. Daydream Communications presented research showing low public awareness of UCCs but strong interest once families learn about them, with parents wanting specialized, compassionate care, clear expectations, insurance clarity, and bilingual support. United Way described its parallel work on a statewide crisis continuum marketing toolkit, using the SAMHSA framework of “someone to talk to, someone to respond, and somewhere safe to go,” and outlined plans to distribute consistent messaging through websites, social media, flyers, and community venues. Members emphasized coordinating with existing platforms and ensuring the marketing reflects the actual experience at UCC sites. DCF then presented on adolescent substance use services, citing data showing high need and low treatment access among Connecticut youth. The department reviewed its ASAM-based continuum, SBIRT efforts in outpatient psychiatric clinics, medication-assisted treatment access, and statewide services such as MST, MST emerging adults, STRIDE, multidimensional family therapy, youth recovery supports, and the AIM matching tool. A new young people peer support program was highlighted, with referrals accepted from families, hospitals, community providers, DCF, youth diversion, and the judicial branch. Questions addressed parent consent, peer matching, and whether the AIM tool could be linked through 211. The meeting concluded with an update from the Connecticut Suicide Advisory Board and its regional boards and grant-funded initiatives. Presenters reviewed the state suicide prevention plan, regional coalition work, postvention response, lethal means safety efforts, and the 988 capacity improvement grant that supports Connecticut’s centralized 988 contact center at United Way. They also shared youth suicide risk data from the Connecticut Youth Risk Behavior Survey, noting recent declines in reported suicidal ideation and attempts, and provided resources for training and materials. No formal votes were taken beyond the approval of the April minutes.

Transcript Highlights:

• </c> with the DEA to look at this substance with the DEA to look at this substance for<00:53:05.839><
• <01:02:52.960><c> detected</c> substance detected substance detected and<01:02:54.720><c> that</c><01
• or regulated substance, banned substance or regulated substance, we<01:19:09.280><c> would</c><01:19
• </c> harms of this subject uh this substance harms of this subject uh this substance and<01:25:04.880
• </c> for about 10 to 15 substances. for about 10 to 15 substances.

Bills: SF0071 , SF0088 , SF0056

Committee: House Judiciary

Transcript Highlights:

• So there's lots of opportunities, you know, and still people other substance use.
• disorder care, and now starting to offer mobile substance use services.
• It's scary to not know what's in a substance that you or someone you love is using.
• The second one is about classifying it as a controlled substance.
• The second one is about classifying it as a controlled substance.

Summary: The Special Commission on xylazine held its first meeting, with House Chair Mindy Domb and Senate Co-Chair John Keenan outlining the commission’s charge and a proposed work plan. The commission is tasked with studying the public health and safety impacts of xylazine in the illicit drug supply, including whether it should be scheduled as a controlled substance, how to regulate its production and distribution, and how to improve outreach and treatment for people exposed to it. Members were told the report deadline had been extended to March 30, 2026, and staff proposed a series of public hearings and working groups leading to a final report. The meeting also included attendance, packet materials, and procedural planning. The first major testimony came from BSAS Director Deirdre Calvert, who described xylazine’s appearance in Massachusetts drug supply data, the state’s public health alerts, and DPH’s partnership with Brandeis, CDC, and harm reduction organizations. She emphasized four priorities: reducing stigma and discrimination in health care, expanding self-directed wound care support and coverage for supplies, expanding access to drug checking and test strips, and supporting low-barrier services such as mobile vans and drop-in centers. Commission members asked about first responder awareness, medical education, and whether harm reduction services might face federal restrictions; Calvert said misinformation remains a problem and noted ongoing training efforts, including collaboration with public safety agencies. Several other speakers reinforced the need for low-barrier care and drug checking. Dr. Raghini Jala, an infectious disease and addiction medicine physician, said xylazine has become a common component of the unregulated opioid supply and urged support for rapid-response education teams, community-based drug checking, and better hospital and detox protocols for xylazine withdrawal and wounds. Recovery coach Alan Young testified from lived experience, describing severe wounds, fear of inadequate withdrawal treatment in emergency settings, and the value of mobile care vans that can provide methadone, buprenorphine, and wound care in the community. Dr. Sarah Wakeman echoed the need for naloxone, rescue breathing, low-threshold treatment, and non-stigmatizing health care settings, while Sarah Macon of the Boston Public Health Commission described Boston’s harm reduction and drug checking work, including on-site testing, wound care, and a decline in opioid mortality. Tracy Green of the Massachusetts Drug Supply Data Stream explained that xylazine has declined in recent samples while metatomidine is rising, said drug checking is increasingly used but still not enough, and argued for more funding, staffing, and statewide access to real-time drug checking and harm reduction services.

Transcript Highlights:

• for students on the dangers of addictive substance use...
• This bill would allow minors to consent to substance use disorder treatment.
• Substance use, addiction, and overdose can happen anywhere and to anyone.
• No matter who you talked to, they knew someone struggling with substance use.
• PTSD, anxiety, depression, and substance use disorders.

Committee: Joint Joint Committee on Mental Health, Substance Use and Recovery

Summary: The Joint Committee on Mental Health, Substance Use and Recovery opened its first public hearing of the 2025–26 session with remarks from the Senate and House chairs outlining the committee’s priorities. They noted recent work on addiction and recovery legislation, the ongoing youth behavioral health crisis, and that members might need to leave periodically for floor votes. The chairs explained hearing procedures, including three-minute testimony limits, written testimony deadlines, and reporting deadlines for Senate and House bills. The hearing then focused on several bills related to youth mental health, overdose prevention, and psychedelic treatment research. A major portion of the hearing centered on bills to improve youth crisis response and overdose prevention. Testimony strongly supported bills to print the 988 Suicide and Crisis Lifeline on student ID cards, with speakers from mental health organizations, crisis centers, and individuals sharing personal stories of depression, suicide attempts, and the importance of making 988 as familiar as 911. Another set of bills would require schools to stock naloxone and provide overdose prevention education. Physicians, harm reduction advocates, students, and grieving family members testified that school-based Narcan access and education could save lives, reduce stigma, and help students recognize overdoses and understand Good Samaritan protections. Senator O’Connor and Tamika Perry also testified for a bill to strengthen substance use prevention education and reduce overdose abandonment, emphasizing the need to teach students about overdose risks and the legal protections for calling 911. The committee also heard testimony on a bill to authorize a pilot program for psychedelic treatment in licensed facilities. Senator Friedman and several medical and behavioral health professionals argued the proposal was a narrow, research-based approach distinct from the broader ballot question rejected in 2024. They said the bill would allow only a small number of supervised clinics to use psychedelics for conditions such as depression, PTSD, anxiety, and substance use disorders, with data reporting and Department of Public Health oversight. Supporters described it as a cautious way to study promising treatments while avoiding unsupervised or commercialized use. Finally, the committee heard support for a bill to create a special commission and five-year strategic plan for children’s behavioral health services, with testimony that the current system is fragmented, difficult for families to navigate, and strained by workforce and funding challenges. No votes or final actions were taken during the hearing; the committee primarily received testimony and questions on the bills.

Transcript Highlights:

• The purpose of the bill is to bridge the gap between substance use disorder guidelines...
• Their main focus is not necessarily substance use disorder. 1,500-plus tests or so.
• Their main focus is not necessarily substance use disorder.
• up, it's a global system that does not really carve out substance use disorder.
• It's a global system that does not really carve out substance use disorder.

Committee: House House Health & Human Services

Transcript Highlights:

• Wright: THE AMENDMENT CHANGES THE LANGUAGE TO ANY INTOXICATING SUBSTANCE TO ANY IMPAIRING SUBSTANCE.
• SOMETIMES SUBSTANCES NOT MARIJUANA BUT SOME SUBSTANCES LIKE MEDICATIONS UNEXPECTEDLY IMPAIR US.
• TO SAY ANY SUBSTANCE THE PERSON KNEW OR SHOULD HAVE KNOWN WAS INTOXICATING.
• CHEMICAL SUBSTANCE OR ANY INHERENT SUBSTANCE.
• BECAUSE ALCOHOL CONTROLLED SUBSTANCE CHEMICAL SUBSTANCE ALL IMPAIR PRESUMABLY SO THAT ADDING CONTROL

Transcript Highlights:

• Substance use disorders are growing at an alarming rate in the United— States.
• 65 or older has or had a substance use disorder.
• Medicaid is the primary payer for substance use disorder treatment.
• We're seeing the deadly substance xylazine end up in, again… It's mixed in substances and a growing problem
• As with treating an older population with substance use disorder.

Committee: Senate Aging (Special) Committee

Keywords: opioid crisis, overdose, naloxone, drug trafficking, law enforcement, treatment, prevention, older adults, Medicaid expansion

Summary: The meeting convened to address the dire opioid crisis affecting communities nationwide, with a particular focus on the alarming rise of opioid use disorder among older adults. Key testimonies highlighted the critical need for a comprehensive approach that encompasses prevention, treatment, and strict law enforcement actions against drug traffickers. Sheriff Dennis Lima from Seminole County outlined successful strategies implemented in Florida, including increased access to naloxone and legislative changes to hold drug dealers accountable for overdoses. Various members expressed a united front on tackling this multifaceted issue, advocating for the expansion of Medicaid and better access to treatment as essential steps to curbing the epidemic.

Transcript Highlights:

• Sometimes substances, not marijuana but some substances like medications, unexpectedly impair us.
• And a solution is, instead of saying ‘or any impairing substance,’ to say ‘or any substance that the
• or chemical substance.
• , chemical substance, or any impairing substance.
• Because alcohol, controlled substance, chemical substance all impair, presumably.

Committee: Senate Appropriations Committee on Criminal and Civil Justice

Summary: The Appropriations Committee on Criminal and Civil Justice met with a quorum and first approved SPB 7014, which terminates the state court system’s mediation and arbitration trust fund; staff noted the fund has no current balance and that filing fees were already redirected in 2011. The bill was reported favorably as a committee bill without objection. The committee then took up CS/SB 48 on alternative judicial procedures for foreclosure sales. Senator Garcia described it as a response to reported abuses in Miami-Dade County, adding longer sale timeframes, stronger notice requirements, rules for alternative sale methods, online auction authorization, and consumer protections for surplus funds. After adopting a technical amendment, members raised concerns about whether the bill was codifying a process they believed should remain with clerks of court and about the new online auction provisions; Senator Garcia ultimately moved to temporarily postpone the bill. Members also approved CS/SB 322, creating a nonjudicial process for sheriffs to remove unauthorized persons from commercial property, and CS/SB 138, which revises DUI-related language from “intoxicating” to “impairing” and allows judicial circuits to create DUI diversion programs. CS/SB 138 drew opposition from some members and testimony from cannabis advocates and defense lawyers who argued the catch-all language was too broad and could sweep in lawful medications or create testing and expungement issues, but it still passed. The committee further reported favorably SB 130 on wrongful incarceration compensation, extending filing deadlines and removing restrictive bars to compensation, and SB 234, which strengthens penalties for violent resistance against law enforcement officers and clarifies that such resistance can lead to life imprisonment if it results in an officer’s death. Both bills received supportive testimony, though SB 234 also drew concerns from defense lawyers about removing language tied to lawful duty and good faith; the sponsor said the bill preserves defenses while focusing on violent resistance. The meeting then adjourned.

Transcript Highlights:

• The purpose of the bill is to bridge the gap between substance use disorder guidelines, payer policies
• The purpose of the bill is to bridge the gap between substance use disorder guidelines, payer policies
• We're the only locally owned independent laboratory specialized in substance use disorder drug testing
• And I also say that differentiating what substance use disorder codes are is necessary.
• Their main focus is not necessarily substance use disorder.

Summary: The House Health and Human Services Committee first heard House Bill 256, which would require school cardiac emergency response plans to address sudden cardiac arrest at school athletic activities and ensure AEDs are clearly marked and accessible at those events. The sponsor and an American Heart Association representative said the bill builds on last year’s law and is meant to improve implementation, not add new equipment costs. Members asked about funding, were told the AEDs are already in place, and the bill received a due pass with no opposition. The committee then took up House Bill 278 on Medicaid reimbursement for toxicology testing in substance use disorder treatment. The sponsor and Southwest Labs argued that current payer policies limit providers’ clinical judgment, that a new flat-rate code for unlimited analytes would improve care, keep Medicaid dollars in New Mexico, and support local laboratories. Several members raised concerns about whether the bill effectively rewrites bundled G-codes, whether it mainly benefits one company, how it affects MCO contracts, GRT/tax issues, and whether the fiscal estimates were realistic. After extensive questioning and conflicting views, a due-pass motion was made but the vote ended in a tie, so the bill did not advance. Finally, the committee considered House Bill 287 to create a permanent, full-time Health and Human Services Committee with a director and expanded membership, similar to other permanent legislative committees. Supporters from advocacy and policy groups said health care is too large and complex to be handled by a part-time interim committee and that year-round staffing would improve oversight and policymaking. Members discussed committee composition, staffing, subpoena power, and the proposed appropriation, and the sponsor said the bill is a starting point that could be refined later. The committee approved HB 287 on a do-pass motion and then adjourned until Monday morning.

Transcript Highlights:

• </c><00:32:55.919><c> use</c> some of the outpatient substance use some of the outpatient substance use
• Substance Abuse Coalition, Alan Johnson. Substance Abuse Coalition, Alan Johnson.
• There has been a substance abuse prevention program for many, many years, and substance abuse now has
• There has been a substance abuse prevention program for many, many years, and substance abuse now has
• There has been a substance abuse prevention program for many, many years, and substance abuse now has

Bills: SB2175 , SB2410 , SB2080 , SB2276 , SB2277 , SB2282 , SB2413 , SB2425 , SB2491 , HB2315 , HB2562 , HB1532 , HB1857 , HB2209 , HB1961 , HB2343 , HB2160 , HB2505 , HB1537 , HB1562 , HB1731 , HB1853 , HB1973 , HB1974

Committee: House Health

Summary: The committee opened a hearing on multiple health-related bills and first took up HB 2315, which would create a Department of Health pilot program allowing eligible employees to defer unused vacation leave in exchange for a payout to help with home purchase assistance. The Department of Health testified in support, saying the proposal could aid recruitment and retention, and United Public Workers also supported it as a creative, cost-effective benefit that could help employees become first-time homebuyers. The chair likewise praised the department’s effort, and there were no questions or opposition before the committee moved on. The committee then heard HB 2562 on workplace violence in health care settings. The Department of Health said it preferred requiring licensed hospitals to adopt workplace-violence prevention policies and public reporting rather than creating a new state program. The Department of Labor and Industrial Relations said it appreciated the intent and explained that, absent a specific standard, enforcement would rely on OSHA’s general duty clause, guidance, and inspections. Nurses and the Hawaii Nurses Association gave emotional testimony describing harassment, threats, doxxing, and fears for patient and worker safety, arguing that existing processes were too slow and that hospitals needed immediate, enforceable requirements. The committee discussed current hospital alarm systems and OSHA enforcement, and Labor said it does inspect hospitals and can receive complaints from employees. HB 1532, concerning importation of large cigars and pipe tobacco, was announced as deferred at the request of the bill’s author so it could be refined with proponents and the Attorney General. The committee also discussed HB 1857, a very large measure redefining qualified health care provider and making extensive changes to health care law; the chair said the House would likely pass it without substantive changes and instead defer the effective date while using the Senate companion bill as the vehicle. Testimony on HB 1857 was generally supportive, including from the Hawaii Association of Nurse Anesthesiology and a certified genetic counselor, though both referenced proposed amendments. Finally, the committee heard HB 2209, which would require insurers to honor a patient’s written assignment of benefits to a substance use disorder treatment provider. The Insurance Division and HMSA opposed the bill as drafted, arguing it would create a special class of providers, raise fraud and litigation concerns, and potentially increase premiums. Treatment providers and advocates strongly supported the measure, saying insurers often refuse direct payment even when patients assign benefits, forcing families to front large sums and delaying access to residential treatment; they argued the bill would improve access and help keep care in Hawaii. A psychiatrist testified that he had not seen fraud in Hawaii and that the bill could help address long wait times for life-saving treatment. The committee also received written support from multiple individuals and organizations, and members began asking questions about HMSA’s network size and wait times, with follow-up information requested."}】【。final json to=commentary 天天中彩票出票 to=commentary code 彩神争霸邀请码 to=commentary 彩票平台招商 to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary ುತ್ತಾರೆ to=commentary

Transcript Highlights:

• community, and people who are currently using substances.
• community, and people who are currently using substances.
• It is another alpha-2 agonist and a veterinary substance that we see.
• I appreciate that you elevated that, just through history, as one substance, as any particular substance
• There are many people who are seeking substance use treatment, and so they enter into a substance use

Summary: The Special Commission on Xylazine convened its second meeting, approved the minutes from its June 23 meeting, and reviewed its timeline and working groups. The co-chairs said the commission’s final report is due to the House and Senate clerks by March 30, 2026, and outlined three working groups focused on regulation/oversight of xylazine, treatment and outreach for exposed patients, and education/training for first responders, clinicians, treatment providers, and people who use substances. Staff will schedule working group meetings, with group presentations planned for December 11, followed by commission meetings in February and March to review and finalize the draft report. Public comment centered on research and practical responses to xylazine contamination in the drug supply. Dr. Tracy Green of Brandeis reviewed recent studies showing severe xylazine-related wounds and amputations in Philadelphia, withdrawal symptoms, the value of wound identification tools, and the usefulness of drug checking in detecting xylazine even when users did not suspect it was present. She urged expanded low-barrier wound care, more access to medications for opioid use disorder, overdose prevention sites, housing, and trauma-informed care, while cautioning that stricter controls could push the market toward other dangerous alpha-2 substances. Commissioners asked about early wound identification, dilution/cutting strategies, supplier engagement, and how to reduce stigma and improve treatment access. Tia Johnson of Boston Medical Center and Boston Health Care for the Homeless testified that xylazine contamination still requires naloxone for overdose response, but sedation can last longer and may require low-dose naloxone, oxygen support, and low-threshold monitoring spaces. She emphasized that xylazine-associated wounds can heal with consistent care, but patients often lose access to services when sent to hospitals unnecessarily. Commissioners discussed reimbursement barriers, especially in MassHealth and behavioral health settings, and the need for wound care to be available within detox and treatment programs rather than requiring transfers. The meeting ended with agreement to continue working group planning and adjournment.

Transcript Highlights:

• </c><00:03:30.560><c> and</c> already banned this substance and already banned this substance and another
• </c><00:14:34.480><c> use</c> toxicity, seizures and substance use toxicity, seizures and substance use
• > that</c><00:41:15.040><c> we</c> substances, and other substances that we substances, and other substances
• </c><00:46:54.960><c> It's</c> is a plant-based substance. It's is a plant-based substance.
• </c> the substance. the substance.

Bills: HB0103 , HB0070 , HB0091

Committee: Senate Judiciary

Transcript Highlights:

• House Bill 777 by Health and Welfare Committee, an act relating to uniform controlled substances, amending
• Section 37-2705, Idaho Code, to revise provisions regarding Schedule I controlled substances and to
• Also number 777 by Health and Welfare Committee, and after relating to uniform controlled substances,
• Code to revise provisions regarding Schedule 1 controlled substances to make technical corrections.
• Amending Section 37-207, Idaho Code, to revise provisions regarding Schedule 2 controlled substances

Transcript Highlights:

• And, um, the, um, the, the, the, the, the, the substances.
• It includes the substance use treatment community.
• The way that we broke this out was clinicians, ...substance use treatment community.
• ... ...one substance kind of gets cracked down on and they’re on to the next.
• And includes information around trends with xylazine and other emergent substances.

Summary: The special commission on xylazine met virtually, called to order by House Chair Mindy Domb, with a quorum present. The commission approved the minutes from its December 11 public meeting and then reviewed the first draft of its final report, which is due to the Legislature by March 30, 2026. Staff explained the report structure, including a commission overview, findings and recommendations from each working group, and appendices with meeting materials and public resources. Commissioners discussed the distinction between licit veterinary xylazine and illicit xylazine in the drug supply, noting that the illicit supply is generally not diverted from legal veterinary sources but obtained through online vendors, and they clarified that xylazine is already classified in Massachusetts as a Schedule 6 substance, so the policy question is whether additional scheduling or penalties are warranted. For the best practices and enforcement section, staff recommended stronger guidance on secure storage and recordkeeping for authorized users, better reporting of diversion, theft, and suspicious orders, and focused enforcement on illicit production and fentanyl trafficking rather than individual possession. Commissioners suggested adding coordination among public safety, law enforcement, and the Attorney General’s office, as well as a state-level approach to emerging drug threats. In the outreach and treatment section, the draft emphasized that existing harm reduction, wound care, naloxone, and mobile outreach programs are effective but need broader coordination, more trauma-informed care, and better education for providers and first responders. Commissioners raised concerns about provider familiarity with xylazine, the need for first responders to include fire personnel and EMS, and the importance of not turning away people with xylazine-related wounds from recovery or treatment settings. The education and training section identified four target audiences: first responders, clinicians, non-clinicians in treatment and outreach settings, and people who use drugs and their families. The draft recommended tailored, stigma-free training and educational materials for each group, with consistent updates, continuing education credits where appropriate, and better access to centralized, real-time data on xylazine and other emerging contaminants. Commissioners discussed the need for centralized reporting and public health surveillance, including existing tools like the BSAS dashboard and StreetCheck, and several members urged the commission to recommend a DPH task force or similar body to monitor future drug supply threats. The meeting ended with staff outlining next steps: a revised draft would be circulated by the end of the week, feedback would be incorporated into a second draft by March 2, and the commission planned to vote on the final report at its March 9 meeting, with a backup meeting later in March if needed.

Transcript Highlights:

• substance, um, and in fact many times do not contain any amount of that substance.
• substance, um, and in fact many times do not contain any amount of that substance.
• substance, um, and in fact many times do not contain any amount of that substance.
• substance, um, and in fact many times do not contain any amount of that substance.
• substance, um, and in fact many times do not contain any amount of that substance.

Committee: Senate Judiciary

Transcript Highlights:

• Speaker, this will substances. Mr.
• Substances Act.
• </c> especially fentanyl related substances. especially fentanyl related substances.
• ,</c><03:51:03.760><c> substance,</c><03:51:04.560><c> or</c> substance is a drug, substance, or substance
• It is the most substance one item.

Transcript Highlights:

• Xylazine is currently not classified as a controlled substance under the federal Controlled Substances
• </c> classified as a controlled substance classified as a controlled substance under<00:45:01.040><c>
• under the federal controlled substance under the federal controlled substance act<00:45:03.040><c> and
• Again, this has been substances.
• </c> possible to overdose on substance? possible to overdose on substance?

Committee: Senate Judiciary